Seronegative spondyloarthropathy-associated inflammatory bowel disease.
Wang CR, Tsai HW.
World J Gastroenterol. 2023 Jan 21;29(3):450-468. doi: 10.3748/wjg.v29.i3.450.
Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis.
McGonagle D, Watad A, Sharif K, Bridgewood C.
Front Immunol. 2021 Mar 19;12:614255. doi: 10.3389/fimmu.2021.614255. eCollection 2021.
Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis.
McGonagle D, David P, Macleod T, Watad A.
Nat Rev Rheumatol. 2023 Dec;19(12):818-827. doi: 10.1038/s41584-023-01038-9. Epub 2023 Nov 2.
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D'Angelo S, Schulz B, Rissler M, Nagar K, Perella C, Coates LC.
Ann Rheum Dis. 2021 May;80(5):582-590. doi: 10.1136/annrheumdis-2020-218808. Epub 2020 Dec 17.
Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis.
Britanova OV, Lupyr KR, Staroverov DB, Shagina IA, Aleksandrov AA, Ustyugov YY, Somov DV, Klimenko A, Shostak NA, Zvyagin IV, Stepanov AV, Merzlyak EM, Davydov AN, Izraelson M, Egorov ES, Bogdanova EA, Vladimirova AK, Iakovlev PA, Fedorenko DA, Ivanov RA, Skvortsova VI, Lukyanov S, Chudakov DM.
Nat Med. 2023 Nov;29(11):2731-2736. doi: 10.1038/s41591-023-02613-z. Epub 2023 Oct 23.
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
Coates LC, Gossec L, Zimmermann M, Shawi M, Rampakakis E, Shiff NJ, Kollmeier AP, Xu XL, Nash P, Mease PJ, Helliwell PS.
RMD Open. 2024 Mar 26;10(1):e003977. doi: 10.1136/rmdopen-2023-003977.
Spondyloarthritides.
Baraliakos X, Braun J.
Best Pract Res Clin Rheumatol. 2011 Dec;25(6):825-42. doi: 10.1016/j.berh.2011.11.006.
Psoriatic arthritis.
Gladman DD.
Rheum Dis Clin North Am. 1998 Nov;24(4):829-44, x. doi: 10.1016/s0889-857x(05)70044-2.
Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Gladman DD, Mease PJ, Bird P, Soriano ER, Chakravarty SD, Shawi M, Xu S, Quinn ST, Gong C, Leibowitz E, Poddubnyy D, Tam LS, Helliwell PS, Kavanaugh A, Deodhar A, Østergaard M, Baraliakos X.
Trials. 2022 Sep 5;23(1):743. doi: 10.1186/s13063-022-06589-y.
Seronegative spondyloarthritides.
Calin A.
Med Clin North Am. 1986 Mar;70(2):323-36.
